Table 1

Vaccine profiles

Pathogen	Disease presentation	Vaccine			Vaccination scenarios (age of vaccination)		Justification
Pathogen	Disease presentation	Efficacy (%)	Coverage (%)	Duration of protection	Baseline scenario	High-potential scenario	Justification
Acinetobacter baumannii—BSI*	BSI	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
A. baumannii—all	All (Bacterial skin infections, BSI, cardiac infections, LRI and thorax infections, UTI)	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Enterococcus faecium	All (bone and joint infections, BSI, cardiac infections, intra-abdominal infections, UTI)	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Enterotoxigenic Escherichia coli	Diarrhoea	60	70	5 years	6 months	–	WHO Preferred Product Characteristics and Expert opinion and Advanced candidate
Extraintestinal Pathogenic E. coli (ExPEC)—BSI*	BSI	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
ExPEC—UTI*	UTI	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
E. coli—non diarrheagenic	Bacterial skin infections, bone and joint infections, BSI, cardiac infections, CNS infections, intra-abdominal infections, LRI and thorax infections and UTI	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Group A Streptococcus	All (bacterial skin infections, bone and joint infections, BSI, cardiac infections)	70	70	5 years	6 weeks	–	WHO Preferred Product Characteristics and Expert opinion
Haemophilus influenzae type B	All (CNS infections, LRI and thorax infections)	59; 92; 93† (69 for LRI)	90	5 years	6, 10, 14 weeks	–	Existing vaccine
Klebsiella pneumoniae—BSI	BSI	70	70	6 months	0 weeks (maternal)	–	Hypothetical vaccine based on expert opinion
K. pneumoniae—all	All (bacterial skin infections, bone and joint infections, BSI, cardiac infections, CNS infections, intra-abdominal infections, LRI and thorax infections, UTI)	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Mycobacterium tuberculosis—M72*	Tuberculosis	50	70	10 years	10 years+boost every 10 years	–	WHO Preferred Product Characteristics and Expert opinion and Advanced candidate
M. tuberculosis—Improved	Tuberculosis	80	70	10 years	0 weeks (at birth) + boost every 10 years	–	WHO Preferred Product Characteristics and Expert opinion
Neisseria gonorrhoeae	Gonorrhoea	70	70	10 years	15 years	–	WHO Preferred Product Characteristics and Expert opinion
Non-typhoidal Salmonella	All (BSI, cardiac infections, diarrhoea, typhoid, paratyphoid and iNTS)	80	70	5 years	6 weeks, 9 months	–	Hypothetical vaccine based on expert opinion
Pseudomonas aeruginosa	BSI, LRI and thorax infections	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Salmonella paratyphi	Typhoid, paratyphoid and iNTS	70	70	5 years	9 months	–	Hypothetical vaccine based on expert opinion
Salmonella typhi	All (BSI, cardiac infections, typhoid, paratyphoid and iNTS)	85	70	15 years	9 months	–	Existing vaccine and Expert opinion
Shigella	All (diarrhoea)	60	70	5 years	6 months	–	WHO Preferred Product Characteristics and Expert opinion and Advanced candidate
S. aureus	All (Bacterial skin infections, bone and joint infections, BSI, cardiac infections, CNS infections, intra-abdominal infections, LRI and thorax infections, UTI)	60	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Streptococcus pneumoniae	BSI, CNS infections, cardiac infections, LRI	29; 58; 58† (27 for LRI)	90	5 years	6, 10, 14 weeks	6, 10, 14 weeks, elderly age group with highest burden	Existing vaccine
S. pneumoniae—Improved*	BSI, CNS infections, Cardiac infections, LRI	70 (50 for LRI)	90	5 years	6 weeks	6 weeks, elderly age group with highest burden	Hypothetical vaccine based on expert opinion

Product characteristics for efficacy and duration of protection for vaccine-derived immunity, and coverage and target population (age of vaccination) for current and future vaccines against bacterial pathogens. The baseline scenario includes 15 pathogens, and the high-potential scenario includes a subset of 7 pathogens.
*The effects of these vaccines were not added to the aggregated impact of vaccination on AMR burden by region and by infectious syndrome.
†Efficacy corresponding to first, second and third doses respectively.
AMR, antimicrobial resistance; bacterial skin infections, bacterial infections of the skin and subcutaneous systems; Bone and joint infections, infections of bones, joints, and related organs; BSI, bloodstream infections; cardiac infections, endocarditis and other cardiac infections; CNS, central nervous system; CNS infections, meningitis and other bacterial central nervous system infections; intra-abdominal infections, peritoneal and intra-abdominal infections; iNTS, invasive non-typhoidal Salmonella spp; LRI, lower respiratory infection; LRI and thorax infections, lower respiratory infections and all related infections in the thorax; typhoid, paratyphoid, and iNTS, typhoid fever, paratyphoid fever, and invasive non-typhoidal Salmonella spp; UTI, urinary tract infections and pyelonephritis; UTI, urinary tract infection.